Fort Vancouver Investment Management’s Iovance Biotherapeutics IOVA Stock Holding History

Fort Vancouver Investment Management’s Portfolio IOVA Stock Details IOVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$21	Buy	+5	New	+$19	﹤0.01%	62

Other funds holding IOVA

CWG

C WorldWide Group Copenhagen, Denmark $4.15B AUM 13.14% 1-Year Est. Return

MCP

Mirador Capital Partners Pleasanton, California $817M AUM 42.46% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

HWAM

Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return

RBI

Raiffeisen Bank International Vienna, Austria $8.53B AUM 46.94% 1-Year Est. Return

Tema ETFs New York $3.09B AUM 72.72% 1-Year Est. Return

TD Asset Management Toronto, Ontario, Canada $115B AUM 41.58% 1-Year Est. Return

Cambridge Investment Research Advisors Fairfield, Iowa $44.6B AUM 28.94% 1-Year Est. Return

LSA

Leonteq Securities AG Zurich, Switzerland $2.91B AUM 56.5% 1-Year Est. Return

Wedbush Securities Los Angeles, California $3.88B AUM 32.38% 1-Year Est. Return

Fort Vancouver Investment Management's IOVA Position: Q2 2026 in Review

Fort Vancouver Investment Management opened a new position in Iovance Biotherapeutics (IOVA) in Q2 2026: 5 shares worth $21. The stake represents ﹤0.01% of the portfolio and ranks #62 among its holdings.

72 funds tracked by Wall St. Rank hold IOVA as of Q2 2026.

Fort Vancouver Investment Management held 5 shares of Iovance Biotherapeutics worth $21 as of Q2 2026.
Iovance Biotherapeutics was a new Fort Vancouver Investment Management position in Q2 2026.
Iovance Biotherapeutics made up ﹤0.01% of Fort Vancouver Investment Management's portfolio in Q2 2026, its #62 holding.
72 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q2 2026.

Based on Fort Vancouver Investment Management's 13F filing for Q2 2026, filed 30 Jul 2026.